Engineering the supernatural: monoclonal antibodies for challenging infectious diseases

The COVID-19 pandemic demonstrated that monoclonal antibodies can be deployed faster than antimicrobials and vaccines. However, the majority of mAbs treat cancer and autoimmune diseases, whereas a minority treat infection. This is in part because targeting a single antigen by the antibody Fab domain...

Descripción completa

Detalles Bibliográficos
Autores principales: Grace, Patricia S, Gunn, Bronwyn M, Lu, Lenette L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612313/
https://www.ncbi.nlm.nih.gov/pubmed/36242952
http://dx.doi.org/10.1016/j.copbio.2022.102818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612313/
https://www.ncbi.nlm.nih.gov/pubmed/36242952
http://dx.doi.org/10.1016/j.copbio.2022.102818

Ejemplares similares